News

Tryptase genotyping helps determine whether a high tryptase level reflects disease or genetics in systemic mastocytosis (SM).

A recent case study highlights how anemia and low platelet counts can be the initial presentation of systemic mastocytosis (SM).

Patients with systemic mastocytosis (SM) face significantly increased risks of melanoma and other skin cancers.

A recently published case report highlighted systemic mastocytosis (SM) as a possible cause of chronic diarrhea.

HT-KIT cut KIT protein levels by more than 80% and halted tumor growth in systemic mastocytosis (SM) models.

Relying on BST levels to diagnose SM doesn’t account for individual variability influenced by genetic and physiological factors.

Several newly approved and experimental treatments have shown promise in the management of systemic mastocytosis.

Indolent SM may be diagnosed despite the absence of classic symptoms associated with this disorder.

Different KIT mutations in patients with systemic mastocytosis (SM) appear to correlate with certain findings under the microscope.

Vitamin supplements may help relieve chronic itch in people with conditions like systemic mastocytosis, especially when applied topically.